Stephen MacMillan has resigned from his roles as chair, president and CEO of Stryker Corporation.
The US-based medical technology firm cited family reasons as the motivation for the departure of MacMillan, who had been chair for two years, CEO for seven years and president for nine years.
MacMillan said: "It has been an enormous privilege to have led Stryker during this period of important change and growth.
“As I look ahead to the next chapter in my life, I remain confident that the team will continue to execute Stryker's strategy with distinction and that the company will enjoy continued success in the future."
Replacing MacMillan as interim CEO is Stryker's current chief financial officer, Curt Hartman, while lead independent director William Parfet will take over as non-executive chairman.
Hartman, who has been with the company since 1990, has served as chief financial officer and vice president since 2009 and his previous roles include holding the post of global president of Stryker Instruments.
Parfet has been a director at Stryker for almost 20 years alongside his role as chair and CEO of drug safety and pharmaceutical development company MPI Research.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...